The estimated Net Worth of Stephen Dale is at least $1.53 Миллион dollars as of 29 January 2024. Dr Dale owns over 11,983 units of Kura Oncology Inc stock worth over $771,682 and over the last 4 years he sold KURA stock worth over $359,435. In addition, he makes $398,934 as Chief Medical Officer at Kura Oncology Inc.
Sign up
Dr D KURA stock SEC Form 4 insiders trading
Dr has made over 2 trades of the Kura Oncology Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 11,983 units of KURA stock worth $231,392 on 29 January 2024.
The largest trade he's ever made was selling 11,983 units of Kura Oncology Inc stock on 29 January 2024 worth over $231,392. On average, Dr trades about 3,030 units every 52 days since 2020. As of 29 January 2024 he still owns at least 38,817 units of Kura Oncology Inc stock.
You can see the complete history of Dr Dale stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Stephen Dale M.D. biography
Dr. Stephen Dale M.D. is the Chief Medical Officer at Kura Oncology Inc.
What is the salary of Dr D?
As the Chief Medical Officer of Kura Oncology Inc, the total compensation of Dr D at Kura Oncology Inc is $398,934. There are 10 executives at Kura Oncology Inc getting paid more, with Kathleen Ford having the highest compensation of $3,485,030.
How old is Dr D?
Dr D is 49, he's been the Chief Medical Officer of Kura Oncology Inc since . There are 16 older and 5 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
What's Dr D's mailing address?
Stephen's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.
Insiders trading at Kura Oncology Inc
Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson и Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.
What does Kura Oncology Inc do?
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
What does Kura Oncology Inc's logo look like?
Complete history of Dr Dale stock trades at Kura Oncology Inc
Kura Oncology Inc executives and stock owners
Kura Oncology Inc executives and other stock owners filed with the SEC include:
-
Kathleen Ford,
Chief Operating Officer -
Troy Wilson,
Chairman of the Board, President, Chief Executive Officer -
Marc Grasso,
Chief Financial Officer and Chief Business Officer -
James Basta,
Chief Legal Officer and Secretary -
Dr. Troy Edward Wilson,
Chairman, CEO & Pres -
Dr. Troy Edward Wilson J.D., Ph.D.,
Chairman, CEO, Pres & Principal Financial Officer -
Dr. Marc Grasso,
CFO & Chief Bus. Officer -
Kathleen Ford,
Chief Operating Officer -
Kirsten Flowers,
Chief Commercial Officer -
Dr. Marc Grasso M.D.,
Advisor -
Dr. Stephen Dale M.D.,
Chief Medical Officer -
Diane Parks,
Independent Director -
Robert Hoffman,
Independent Director -
Faheem Hasnain,
Lead Independent Director -
Thomas Malley,
Independent Director -
Steven Stein,
Independent Director -
Mary Szela,
Independent Director -
Bridget Martell,
Acting Chief Medical Officer -
Kirsten Flowers,
Chief Commercial Officer -
Stephen Dale,
Chief Medical Officer -
Thomas Doyle,
Principal Accounting Officer & Sr. VP of Fin. and Accounting -
Dr. Nic G. Scalfarotto,
Sr. VP of Regulatory Affairs -
Dr. Roger Bakale Ph.D.,
VP and Head of CMC, Clinical & Commercial Manufacturing -
Teresa Brophy Bair Esq., J.D.,
Chief Legal Officer & Corp. Sec. -
James E. Basta J.D., Esq.,
Chief Compliance Officer & Corp. Sec. -
Pete De Spain,
VP of Investor Relations & Corp. Communications -
Teresa Brophy Bair,
Chief Legal Officer -
Antonio Gualberto,
Head of Development & CMO -
Pingda Ren,
SVP Chemistry&Pharma Sciences -
Annette North,
SVP, General Counsel -
Carol Schafer,
-
Helen Louise Collins,
-
Brian T. Powl,
Chief Commercial Officer -
Thomas James Doyle,
SVP, Finance & Accounting